Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitor

This page shows the latest JAK inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

plus Merck &Co’s checkpoint inhibitor Keytruda for the first-line treatment of advanced renal cell carcinoma (RCC). ... Pfizer’s Janus kinase (JAK) inhibitor Xeljanz also grew by 18% operationally, with a 16% growth in the US and a 21% increase in

Latest news

More from news
Approximately 6 fully matching, plus 83 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    The decade-long $5.1bn alliance, announced in July, came on the heels of a long relationship between the two companies that had already yielded a late-stage candidate, JAK inhibitor ... and filgotinib’s anticipated launch this year meets expectations

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite ... checkpoint

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... t the only oral JAK inhibitor developer with its eye on that particular prize.

  • Deal Watch January 2018

    Acquisition company -  remaining 90%. 9, 000. Impact Biomedicines/ Celgene. Fedratinib, highly selective JAK2 kinase inhibitor for myelofibrosis (p3) and polycythemia vera. ... Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302,

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...